BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20370706)

  • 1. Cyclin-dependent kinase 4/6 (cdk4/6) inhibitors: perspectives in cancer therapy and imaging.
    Graf F; Mosch B; Koehler L; Bergmann R; Wuest F; Pietzsch J
    Mini Rev Med Chem; 2010 Jun; 10(6):527-39. PubMed ID: 20370706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
    Chen F; Liu C; Zhang J; Xu W; Zhang Y
    Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
    Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Wang Z; Shi W; Mao Y; Yu J; Ke Y; Xia G
    Eur J Med Chem; 2020 May; 193():112239. PubMed ID: 32200202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4 and CDK6 kinases: From basic science to cancer therapy.
    Fassl A; Geng Y; Sicinski P
    Science; 2022 Jan; 375(6577):eabc1495. PubMed ID: 35025636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D-CDK4/6 functions in cancer.
    Gao X; Leone GW; Wang H
    Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CDK4 and CDK6: From Discovery to Therapy.
    Sherr CJ; Beach D; Shapiro GI
    Cancer Discov; 2016 Apr; 6(4):353-67. PubMed ID: 26658964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment.
    Liu N; Fang H; Li Y; Xu W
    Curr Med Chem; 2009; 16(36):4869-88. PubMed ID: 19929781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.
    Klein ME; Kovatcheva M; Davis LE; Tap WD; Koff A
    Cancer Cell; 2018 Jul; 34(1):9-20. PubMed ID: 29731395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
    VanArsdale T; Boshoff C; Arndt KT; Abraham RT
    Clin Cancer Res; 2015 Jul; 21(13):2905-10. PubMed ID: 25941111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.
    Tadesse S; Bantie L; Tomusange K; Yu M; Islam S; Bykovska N; Noll B; Zhu G; Li P; Lam F; Kumarasiri M; Milne R; Wang S
    Br J Pharmacol; 2018 Jun; 175(12):2399-2413. PubMed ID: 28800675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
    Du Q; Guo X; Wang M; Li Y; Sun X; Li Q
    J Hematol Oncol; 2020 May; 13(1):41. PubMed ID: 32357912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors.
    Zhao H; Hu X; Cao K; Zhang Y; Zhao K; Tang C; Feng B
    Eur J Med Chem; 2018 Sep; 157():935-945. PubMed ID: 30165341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies.
    Guan H; Du Y; Han W; Shen J; Li Q
    Anticancer Agents Med Chem; 2017; 17(5):646-657. PubMed ID: 28044938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy.
    Nardone V; Barbarino M; Angrisani A; Correale P; Pastina P; Cappabianca S; Reginelli A; Mutti L; Miracco C; Giannicola R; Giordano A; Pirtoli L
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer.
    Ramos N; Baquero-Buitrago J; Ben Youss Gironda Z; Wadghiri YZ; Reiner T; Boada FE; Carlucci G
    J Nucl Med; 2020 Mar; 61(3):437-442. PubMed ID: 31481582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.
    Casimiro MC; Velasco-Velázquez M; Aguirre-Alvarado C; Pestell RG
    Expert Opin Investig Drugs; 2014 Mar; 23(3):295-304. PubMed ID: 24387133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4/6 inhibitors in breast cancer.
    Dukelow T; Kishan D; Khasraw M; Murphy CG
    Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
    Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
    Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.